Skip to main content
AROVELLA THERAPEUTICS LIMITED logo

AROVELLA THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ALA ISIN · AU0000182784 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,561 across all filing types
Latest filing 2026-05-25 Share Issue/Capital Cha…
Country AU Australia
Listing ASX ALA

About AROVELLA THERAPEUTICS LIMITED

https://www.arovella.com

Arovella Therapeutics Limited focuses on the development of innovative immunotherapies for cancer treatment. The company utilizes an invariant Natural Killer T (iNKT) cell therapy platform to create off-the-shelf treatments for blood cancers and solid tumors. Its lead candidate, ALA-101, features iNKT cells engineered with a Chimeric Antigen Receptor (CAR) to target CD19-expressing malignancies. Unlike traditional autologous CAR-T therapies, the iNKT platform is designed for allogeneic use, potentially reducing manufacturing complexity and increasing patient access. The company’s research extends to combining iNKT cells with other technologies to address a broader range of oncological indications, leveraging the innate and adaptive immune characteristics of iNKT cells to improve therapeutic outcomes.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - ALA 4 pages 14.7KB
Share Issue/Capital Change Classification · 75% confidence The document is an ASX Appendix 3H form notifying the cessation (expiry) of unexercised options, which is a change in the company’s capital structure (securities ceasing). This is not a financial statement or earnings release but an announcement of a capital change. Under FinancialReports taxonomy, this aligns with Share Issue/Capital Change (SHA).
2026-05-25 English
Notification of cessation of securities - ALA 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for Arovella Therapeutics Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or other report content. The document is short (3427 characters) and is a regulatory announcement about securities cessation, which fits the category of Regulatory Filings (RNS) as it does not fit other more specific categories like capital changes or share issues, which usually involve new issuance rather than cessation. Therefore, the best classification is Regulatory Filings (RNS).
2026-05-07 English
Arovella Appoints Acting CEO 2 pages 222.6KB
Board/Management Information Classification · 100% confidence The document is an ASX release announcing the appointment of Dr. Nicole Van Der Weerden as Acting CEO following the resignation of the previous CEO. It includes biographical information about the new Acting CEO and statements from the Chairman. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no capital changes, and no other report types. The document is a management announcement regarding a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4087 characters, which is consistent with a typical announcement rather than a full report.
2026-05-06 English
Arovella Presents at ISCT Conference in Dublin 3 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is an ASX release dated 7 May 2026 from Arovella Therapeutics Limited. It announces the company's presentation of pre-clinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting. The content includes detailed scientific data on CAR-iNKT cell therapy targeting CLDN18.2-positive cancers, including experimental results, figures, and scientific citations. The document is lengthy (over 12,000 characters) and contains substantive scientific and technical information rather than a brief announcement or summary. It is not a financial report, earnings release, or regulatory filing. It is a detailed investor and public presentation of scientific data and company progress, consistent with an Investor Presentation (IP). There is no indication that this is a full Annual Report, Audit Report, or Management Report. It is not a transcript of a call or a voting result announcement. Therefore, the best fit is Investor Presentation (IP).
2026-05-06 English
Final Director's Interest Notice x4 8 pages 324.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities interests of multiple directors who have ceased to be directors, including their holdings and relevant interests. The content is focused on reporting personal share transactions or holdings by company directors. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure of directors' shareholdings and interests, which aligns with the definition of Director's Dealing filings. Therefore, the appropriate classification is 'DIRS' (Director's Dealing). The document length and detail support a high confidence in this classification.
2026-05-06 English
Board Refresh and CEO Resignation 2 pages 181.9KB
Board/Management Information Classification · 95% confidence The document is an ASX release dated 4 May 2026 from Arovella Therapeutics Limited announcing changes in the company's board of directors and the resignation of the CEO. It details the resignation of several directors and the CEO, the appointment of a new chairman, and the composition of the refreshed board. There is no financial data, no mention of financial results, no report attached or referenced, and no discussion of other report types. The content is focused solely on management and board changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 5649 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report content. Hence, the classification is MANG with high confidence.
2026-05-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.